See more : H-One Co.,Ltd. (5989.T) Income Statement Analysis – Financial Results
Complete financial analysis of Cybin Inc. (CYBN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cybin Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mount Logan Capital Inc. (PYCFF) Income Statement Analysis – Financial Results
- Sanwa Holdings Corporation (5929.T) Income Statement Analysis – Financial Results
- Bio Green Energy Tech Public Company Limited (BIOTEC.BK) Income Statement Analysis – Financial Results
- Honor (7709.TWO) Income Statement Analysis – Financial Results
- Country Group Holdings Public Company Limited (CGH.BK) Income Statement Analysis – Financial Results
Cybin Inc. (CYBN)
About Cybin Inc.
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 864.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 424.00K | 251.00K | 168.00K | 664.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -424.00K | -251.00K | -168.00K | 200.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 23.15% | 0.00% | 0.00% | 0.00% |
| Research & Development | 32.36M | 26.15M | 17.59M | 3.30M | 321.60K | 0.00 | 0.00 |
| General & Administrative | 29.80M | 24.49M | 44.79M | 22.48M | 1.36M | 0.00 | 0.00 |
| Selling & Marketing | 2.79M | 881.00K | 1.47M | 4.95M | 117.60K | 0.00 | 0.00 |
| SG&A | 46.47M | 25.37M | 46.25M | 27.42M | 1.63M | 80.52K | 127.22K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -482.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 78.84M | 51.52M | 63.84M | 30.72M | 1.94M | 80.52K | 127.22K |
| Cost & Expenses | 78.84M | 51.52M | 63.84M | 31.39M | 1.94M | 80.52K | 127.22K |
| Interest Income | 619.00K | 603.00K | 241.00K | 60.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 241.00K | 10.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 260.00K | 251.00K | 168.00K | 49.00K | 1.95M | 161.14K | 0.00 |
| EBITDA | -78.58M | -51.29M | -63.67M | -32.16M | 9.60K | -80.52K | -127.22K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -3,520.25% | 0.00% | 0.00% | 0.00% |
| Operating Income | -78.84M | -54.94M | -63.60M | -30.46M | -1.95M | -80.52K | -127.22K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -3,525.93% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 756.00K | 4.03M | -3.79M | -1.19M | 9.60K | -20.00K | 4.00 |
| Income Before Tax | -78.08M | -47.49M | -67.63M | -32.22M | -1.94M | -100.52K | -127.22K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -3,729.17% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.45M | 3.79M | 10.00K | 9.60 | -161.14K | 0.00 |
| Net Income | -78.08M | -40.04M | -71.42M | -32.22M | -1.94M | -100.52K | -127.22K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -3,729.17% | 0.00% | 0.00% | 0.00% |
| EPS | -9.50 | -0.22 | -0.43 | -0.32 | -0.05 | -0.01 | -0.01 |
| EPS Diluted | -9.41 | -0.22 | -0.43 | -0.32 | -0.04 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 8.22M | 185.43M | 167.29M | 100.01M | 40.50M | 13.89M | 13.89M |
| Weighted Avg Shares Out (Dil) | 8.30M | 185.43M | 167.29M | 100.01M | 49.98M | 13.89M | 13.89M |
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced positive safety, pharmacokinetic (“PK”) and pharmacodynamic (“PD”) data from its Phase...
Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today outlined its recent positive Phase 2 CYB003 topline results in MDD...
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
Mental health has been one of the hot topics in the medical industry over the past few years. Widespread awareness was brought to the public eye during the COVID-19 pandemic as people in prolonged lockdowns struggled with isolation as well...
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that the United States Patent and Trademark Office (“USPTO”) has...
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced the presentation of four posters at the American College of...
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced positive Phase 2 topline safety and efficacy data for CYB003,...
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that it will discuss its topline Phase 2 safety and efficacy...
Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next generation psychedelic-based treatment options, today announced that it will host an R&D briefing on Thursday,...
Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced a poster presentation at Neuroscience 2023 hosted by the Society...
Cybin Reports Second Quarter Financial Results and Recent Business Highlights
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation 2.0 psychedelic treatment options, today reported unaudited financial results for its second quarter ended September...
Source: https://incomestatements.info
Category: Stock Reports